ITGB2 and pancreatic neoplasm: First, we performed a MTT assay to investigate the dose dependent inhibitory effect of canertinib, afatinib and erlotinib TKIs on pancreatic cancer cells (CD18/HPAF and Capan-1) for an incubation period of 24 h.